Claim Missing Document
Check
Articles

Found 3 Documents
Search

The Efficacy of NeuroAid™ (MLC601) in Modulating NF-κB Expression and Improving Outcomes in Traumatic Brain Injury: A Preclinical Study Dedy Chandra Hariyono; Hanis Setyono; Ida Bagus Budhi Surya Adnyana
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1309

Abstract

Background: Traumatic brain injury (TBI) represents a significant global health concern, leading to substantial mortality and long-term disability. The intricate pathophysiology of TBI involves primary mechanical damage followed by a cascade of secondary injury events, including neuroinflammation, apoptosis, and oxidative stress. The nuclear factor kappa B (NF-κB) signaling pathway plays a pivotal role in orchestrating the inflammatory response post-TBI and has emerged as a potential therapeutic target. This preclinical study aimed to investigate the efficacy of NeuroAid™ (MLC601), a traditional herbal medicine, in modulating NF-κB expression and improving outcomes in a rat model of TBI. Methods: This study employed a true experimental in vivo design with a post-test only control group. Male Wistar rats (n=18) were randomly divided into two groups: a control group (n=9) subjected to TBI via a weight-drop method, and an experimental group (n=9) subjected to the same TBI procedure followed by intraperitoneal administration of NeuroAid™ (MLC601) at a dose of 2.5 mg/kg body weight at 5 minutes, 8 hours, and 16 hours post-injury. NF-κB expression in brain tissue samples collected 1 hour after the final dose was assessed using immunohistochemistry and quantified by an immunoreactivity score considering both the intensity and percentage of NF-κB expression. Results: Immunohistochemical analysis revealed the presence of NF-κB expression in both the nucleus and cytoplasm of neurons in both the control and experimental groups. While the experimental group treated with NeuroAid™ (MLC601) exhibited a lower average immunoreactivity score (0.93) compared to the control group (1.29), the difference in NF-κB expression between the two groups was not statistically significant (p = 0.122). Conclusion: In this preclinical study using a Wistar rat model of TBI, the administration of NeuroAid™ (MLC601) did not result in a statistically significant reduction in NF-κB expression compared to the untreated control group. Although a trend towards lower NF-κB expression was observed in the NeuroAid™-treated group, further research with larger sample sizes, different dosages, and extended treatment durations is warranted to fully elucidate the potential therapeutic effects of NeuroAid™ (MLC601) in the management of traumatic brain injury.
Atypical Presentation of Cerebellopontine Angle Dermoid Cyst: A Case of Secondary Trigeminal Neuralgia Prima Budi Prayogi; Galih Indra Permana; Hanis Setyono; Ferry Wijanarko; Geizar Arsika Ramadhana; Muhammad Fauzan Jauhari
Open Access Indonesian Journal of Medical Reviews Vol. 5 No. 4 (2025): Open Access Indonesian Journal of Medical Reviews
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/oaijmr.v5i4.753

Abstract

Dermoid cysts are rare congenital ectodermal inclusion cysts, accounting for a small percentage of all intracranial tumors. Their occurrence in the cerebellopontine angle (CPA) is infrequent, and presentation as isolated trigeminal neuralgia (TN) is considered atypical. This study underscores that rare congenital lesions like dermoid cysts can manifest with relatively common neurological symptoms, prompting clinicians to consider a broader differential diagnosis A 60-year-old female presented with a two-year history of paroxysmal, shock-like pain in the left cheek and intraoral area, triggered by light touch, consistent with trigeminal neuralgia. Neurological examination was otherwise largely unremarkable initially, though the pain significantly impacted her quality of life and nutritional intake, leading to weight loss. Magnetic Resonance Imaging (MRI) revealed an extra-axial lesion in the CPA, compressing the trigeminal nerve. The lesion exhibited characteristics suggestive of an epidermoid or arachnoid cyst initially, but with features also compatible with a dermoid cyst. The patient underwent a retrosigmoid craniotomy for microsurgical excision of the lesion. Intraoperatively, a cystic lesion with contents suggestive of a dermoid cyst was found adherent to the trigeminal nerve and surrounding structures. Histopathological examination confirmed the diagnosis of a dermoid cyst. Postoperatively, the patient experienced significant relief from her trigeminal neuralgia. In conclusion, CPA dermoid cysts, though rare, should be considered in the differential diagnosis of secondary trigeminal neuralgia, even in atypical presentations. MRI is crucial for diagnosis, and surgical excision aiming for maximal safe resection is the mainstay of treatment, offering potential for symptom resolution. Long-term follow-up is necessary due to the potential for recurrence if the residual cyst wall remains. This case underscores the importance of considering rare pathologies in common clinical presentations.
The Efficacy of NeuroAid™ (MLC601) in Modulating NF-κB Expression and Improving Outcomes in Traumatic Brain Injury: A Preclinical Study Dedy Chandra Hariyono; Hanis Setyono; Ida Bagus Budhi Surya Adnyana
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1309

Abstract

Background: Traumatic brain injury (TBI) represents a significant global health concern, leading to substantial mortality and long-term disability. The intricate pathophysiology of TBI involves primary mechanical damage followed by a cascade of secondary injury events, including neuroinflammation, apoptosis, and oxidative stress. The nuclear factor kappa B (NF-κB) signaling pathway plays a pivotal role in orchestrating the inflammatory response post-TBI and has emerged as a potential therapeutic target. This preclinical study aimed to investigate the efficacy of NeuroAid™ (MLC601), a traditional herbal medicine, in modulating NF-κB expression and improving outcomes in a rat model of TBI. Methods: This study employed a true experimental in vivo design with a post-test only control group. Male Wistar rats (n=18) were randomly divided into two groups: a control group (n=9) subjected to TBI via a weight-drop method, and an experimental group (n=9) subjected to the same TBI procedure followed by intraperitoneal administration of NeuroAid™ (MLC601) at a dose of 2.5 mg/kg body weight at 5 minutes, 8 hours, and 16 hours post-injury. NF-κB expression in brain tissue samples collected 1 hour after the final dose was assessed using immunohistochemistry and quantified by an immunoreactivity score considering both the intensity and percentage of NF-κB expression. Results: Immunohistochemical analysis revealed the presence of NF-κB expression in both the nucleus and cytoplasm of neurons in both the control and experimental groups. While the experimental group treated with NeuroAid™ (MLC601) exhibited a lower average immunoreactivity score (0.93) compared to the control group (1.29), the difference in NF-κB expression between the two groups was not statistically significant (p = 0.122). Conclusion: In this preclinical study using a Wistar rat model of TBI, the administration of NeuroAid™ (MLC601) did not result in a statistically significant reduction in NF-κB expression compared to the untreated control group. Although a trend towards lower NF-κB expression was observed in the NeuroAid™-treated group, further research with larger sample sizes, different dosages, and extended treatment durations is warranted to fully elucidate the potential therapeutic effects of NeuroAid™ (MLC601) in the management of traumatic brain injury.